ScienceOsteoporosis treatments reportedly draw renewed interest from drugmakers and biotech investors
STAT reports that a long-awaited regulatory change has helped spur pharmaceutical industry interest in osteoporosis medicines.
TLDR
Drugmakers and biotech venture capital investors are showing renewed interest in osteoporosis treatments, STAT reports. The outlet points to a long-awaited regulatory change as an incentive for the pharmaceutical industry.
Osteoporosis treatments reportedly draw renewed interest from drugmakers and biotech investors
STAT reports that a long-awaited regulatory change has helped spur pharmaceutical industry interest in osteoporosis medicines.
TLDR
Drugmakers and biotech venture capital investors are showing renewed interest in osteoporosis treatments, STAT reports. The outlet points to a long-awaited regulatory change as an incentive for the pharmaceutical industry.
